Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

refractory lymphoma

  • 0 views
  • 15 Apr, 2021
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

  • 0 views
  • 14 Feb, 2021
  • 16 locations
An Open-label Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists

  • 0 views
  • 13 Feb, 2021
  • 13 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

chemotherapy regimen
total bilirubin
vismodegib
solid tumors
gilbert's syndrome
  • 6087 views
  • 05 May, 2021
  • 1012 locations
CMP-001 for Relapsed and Refractory Lymphoma

patients with relapsed and refractory lymphomas.

cancer
lymphoma
measurable disease
hodgkin's disease
refractory lymphoma
  • 1 views
  • 05 May, 2021
  • 1 location
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma

- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)

dexamethasone
combination chemotherapy
hodgkin's disease
cell transplantation
  • 5 views
  • 07 Nov, 2020
  • 1 location
A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.

multiple myeloma
hematologic malignancy
cancer
rituximab
lymphoma
  • 56 views
  • 27 Jan, 2021
  • 9 locations
Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, single-arm, multi-center, dose-escalation study for individuals with relapsed or refractory classical Hodgkin's Lymphoma or B-cell Non Hodgkin's Lymphoma.

lymphoma
measurable disease
tg-1501
b-cell lymphoma
refractory classical hodgkin lymphoma
  • 13 views
  • 18 Apr, 2021
  • 9 locations
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central …

  • 0 views
  • 10 Apr, 2021
  • 15 locations